Scientists at the University of Osaka have developed a method to recreate human B cells with germinal center features using three immune signals, which closely match those found in human tonsils. This breakthrough could help improve vaccine-induced antibody responses and identify targets for autoimmune disease.
Researchers identified a natural antibody, anti-NMDAR1, that may protect the brain after traumatic brain injury, reducing the risk of depression and PTSD. The study found that Marines with higher levels of the antibody had lower depression and PTSD symptoms after a TBI.
A Korea University study found that an mRNA-based influenza vaccine elicits a more diverse and broader serum antibody repertoire than traditional vaccines. This leads to greater binding and neutralizing breadth against diverse influenza strains, suggesting potential for broader, longer-lasting protection.
Researchers developed a recombinant, nanobody-based antivenom that offers broad protection against venom from geographically diverse cobra and king cobra species in India. The antivenom neutralizes venom activity and prevents venom from binding to its target receptor, showing promising results in mice challenged with venom.
A team of researchers from the University of Osaka found that cells producing IgG1 antibodies have advantages over those producing IgM antibodies, including better antigen presentation, survival, and bone marrow migration. These advantages may lead to long-term immune protection and inform the development of more effective vaccines.
A phase 2 clinical trial found that a monoclonal antibody targeting interleukin-6 achieved sustained reductions in inflammation biomarkers for six months in patients with chronic kidney disease. The therapy, known as pacibekitug, was well-tolerated and showed favorable effects on additional biomarkers associated with cardiovascular risk.
Researchers at La Jolla Institute for Immunology have developed a vaccine that uses T cells to fight Zika virus, but one vaccine, with both antibody and T cell protection, showed long-term protection against the virus. This discovery offers a new hope in the fight against Zika and its close viral relatives.
Scientists have identified multiple targets for antibodies that could treat Crimean-Congo hemorrhagic fever, a deadly virus spread by ticks. The research found that antibodies targeting the nucleocapsid protein offer protection against the virus, regardless of strain, and could lead to the development of new treatments.
A new study from Arizona State University finds that past immune encounters can predict future vaccine response, opening a path toward more personalized vaccination strategies. Researchers analyzed blood samples from over 4,000 people, identifying antibody signatures that distinguish strong responders from weak ones.
A study identified novel autoantibodies associated with idiopathic myelopathy, specifically those related to vitamin B12 transport. Central nervous system vitamin B12 deficiency was also found in affected individuals. The findings suggest a potential diagnostic approach for myelopathy
Researchers uncover the placenta distinguishes between antibodies and albumin, allowing for the design of long-acting biologic medicines with reduced fetal exposure. Fusion of IgG antibodies to albumin inhibits transport across the placenta, enabling the development of safer treatments during pregnancy.
Researchers at Tulane University discovered that vesper bats have two distinct copies of genes producing antibodies, which helps them recognize and fight infections. This finding opens up new areas of study on the evolution of immunity and how animals respond to diseases.
Researchers at KAIST have created an antibody that precisely targets intracellular cancer mutations using computational methods. The antibody selectively recognizes only cancer cells carrying the KRAS(G12D) mutation, demonstrating its potential for precision antibody therapeutics.
Clesrovimab, a long-acting monoclonal antibody, demonstrates safety and efficacy in reducing severe respiratory syncytial virus (RSV) disease in high-risk infants over two RSV seasons. The study supports the use of clesrovimab in children at increased risk for severe RSV disease during their second season.
Researchers at Tohoku University have discovered a previously unknown pathway for B-cell development in chickens, bypassing the bursa of Fabricius. The discovery reveals that B cells originate in the bone marrow and migrate to the cecal tonsils, establishing an IgA-mediated intestinal barrier.
The new journal features cutting-edge research across basic, clinical, and translational immunology. It is designed to connect researchers across the full breadth of immunology, deepening understanding of the immune system in health and disease.
Scientists at La Jolla Institute for Immunology and Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV's defenses. The vaccine resulted in the best HIV-fighting antibody response ever seen in primates, with human trials now underway.
A Michigan State University team discovered that two closely-related proteins STAG1 and STAG2 play distinct roles during antibody-gene assembly. STAG2 acts as a molecular gatekeeper, preventing oversized DNA loops, while STAG1 promotes long-range DNA interactions needed for assembling antibody genes.
Scientists have identified a unique chimeric RNA called UBA1-CDK16 that plays important roles in women's blood cell development and disease severity. The findings suggest the chimeric RNA may serve as a natural brake to protect women from excessive autoimmune activity.
A study by Okayama University researchers revealed that SARS-CoV-2 antibody levels can assess infection history, symptom severity, and cognitive complications in long COVID. The findings suggest that declining S-antibody levels may indicate a greater risk of neurological complications.
Researchers create a hydrogel-based oral formulation that coats the esophageal lining and releases antibodies like infliximab to treat inflammatory conditions. The formulation reduces side effects by temporarily loosening cell-cell junctions, allowing larger molecules to pass through.
A new study has overturned longstanding ideas about how germinal centers function, revealing that they are far more selective than once thought. The findings suggest that the immune system ultimately produces stronger antibodies by repeating a noisy, almost random process over and over across many germinal centers.
Scientists discovered a new way cells fight infection, using a method called antibody-directed xenophagy (ADX), which can digest bacteria and viruses inside infected cells. ADX is triggered by a protein called TRIM21, which flags invading pathogens for destruction.
A recent study by Rockefeller University researchers provides the most comprehensive view to date of how HIV-1 escapes broadly neutralizing antibodies. The study identified over 100 mutations that enable viral strains to resist these antibodies, with some requiring only a single amino acid change.
Researchers at La Jolla Institute for Immunology discovered that FluMist can trigger an immune response directly in nasal tissue, training immune cells to recognize and fight influenza virus infection. This response stays in the upper airways and cannot be detected via blood samples.
Researchers have made a breakthrough in developing a novel platform that harnesses the immune system's ability to produce therapeutic proteins. By editing hematopoietic stem cells with CRISPR gene-editing tools, they were able to create a long-term, boostable source of antibodies capable of protecting against deadly influenza infection...
Researchers at Boston Children's Hospital have identified a mechanism for immune cells to recycle defective or autoreactive antibodies by editing their genes. The new process uses an enzyme called RAG to swap out light chains with nearby new ones, often making them non-defective and functional.
Researchers at Scripps Research create a nanodisc platform that preserves key parts of viral surface proteins, allowing for better understanding of antibody interactions. This approach can be applied to other viruses with similar membrane-embedded proteins, such as influenza and SARS-CoV-2.
Researchers have mapped the molecular mechanism behind allergic reactions and developed tailored antibodies to block life-threatening responses. The findings suggest a new approach to targeting the most important allergens and provide a starting point for developing more precise treatments for severe allergy.
Researchers at Karolinska Institutet have mapped immune gene variation across multiple global populations, identifying common genetic variants that affect antibody production. The findings may contribute to understanding infection susceptibility and inform vaccine design.
Researchers at Cold Spring Harbor Laboratory found that antibodies produced in response to cancer can attack the brain, causing autoimmune diseases like lupus and multiple sclerosis. The study suggests that these antibodies may be harnessed to develop new treatments for triple-negative breast cancer.
A new study suggests that autoantibodies from Long COVID patients can induce persistent pain-like symptoms in mice, providing evidence for a potential causal role of autoantibodies in the condition. The research also highlights distinct biological subgroups and offers hope for targeted antibody-based therapies.
Researchers reveal that skin-cell calcium channel TRPV3 is activated by plant-derived fragrant molecules, leading to enhanced immune responses and potential new vaccine adjuvants. The study provides a novel understanding of immune crosstalk and offers a safer approach to enhancing vaccine efficacy.
Rice bioengineer Omid Veiseh has been awarded a $2.2 million grant to develop implantable cell factory platforms that can deliver therapeutic antibodies over extended periods. The platform aims to reduce dosing frequency and improve access to biologic therapies in low- and middle-income countries.
Researchers at UCSF have discovered a new therapeutic target, SRC, present on up to half of all tumors, which can be targeted with antibody drugs. The enzyme, normally hidden inside cells, is exposed on the surface of tumor cells due to an overactive disposal system, making it an easy target for cancer-killing antibodies.
Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.
Researchers discovered Marburg virus enters human cells up to 300 times more efficiently than Ebola, thanks to its unique entry protein. A nanobody has been identified to block its attachment to the receptor, providing a potential therapeutic strategy.
Researchers have identified three new proteins, called epitopes, that help the body determine 'safe' foods, aiding in food tolerance and allergy understanding. The epitopes were found in seed proteins from corn, wheat, and soybean, and interact with regulatory T cells to inform tolerance-or-rejection decisions.
A randomized, double-blind clinical trial found that a natural fungal supplement, FoTv, reduced short-term vaccine side effects and helped antibodies last longer in people who had not previously been exposed to COVID-19. The study suggests that FoTv may help strengthen vaccine protection without increasing side effects.
Researchers at Fred Hutchinson Cancer Center developed new genetically human monoclonal antibodies that prevent EBV from infecting immune cells. The study highlights one of the antibodies that successfully blocked infection in mice with human immune systems.
Researchers developed an AI-driven pipeline to create functional intracellular antibodies, overcoming major barriers in intrabody development. The approach successfully redesigned structures compatible within the cellular environment, enabling high target specificity and stability.
A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...
A novel viral vector, AAVT42, efficiently delivers therapeutic genes to the brain, restoring memory and protecting neuronal structures in multiple models of Alzheimer's disease. BDNF treatment achieves significant cognitive rescue, facilitating structural repair and suppressing harmful pathways.
Researchers identified Fab antibody fragments that target the IgE Cε2 domain, effectively stripping IgE from mast cells. The most potent Fab clones showed rapid efficacy in cellular assays and in vivo anaphylaxis models, demonstrating potential as a next-generation anti-allergy therapy.
Researchers propose a new conceptual framework for neutrophils, highlighting their dynamic and adaptable nature. The study reveals neutrophils' functional diversification and immunological memory capabilities, opening avenues for innovative therapeutic strategies.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Researchers at Colorado State University used AI to modify antibodies into stable intrabodies that can visualize histone modifications in real-time. This allows for better understanding of gene expression and its relationship with cancer and other disorders. The team created 19 new antibody-based probes with a 70% success rate, signifi...
Researchers developed a new way to stimulate the immune system to attack tumor cells by blocking an immune checkpoint. They created multifunctional molecules called AbLecs, which combine a lectin with a tumor-targeting antibody, and showed they could boost the immune response to cancer cells.
MIT researchers have found a new way to create solid particles of highly concentrated antibodies, suspended in a solution, which can be injected using a standard syringe. This advance could make antibody treatments more convenient and accessible for patients, particularly older people with difficulty visiting hospitals.
Researchers used AI to identify a new viral surface protein that triggers the production of neutralizing antibodies, offering a breakthrough for developing effective vaccines and antibody therapies. The discovery could also provide insights into treating smallpox, a related virus posing a bioterrorism risk.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Researchers at UC Santa Barbara propose a cyst-targeted therapy using monoclonal antibodies to interrupt the runaway growth of fluid-filled sacs in polycystic kidney disease. The treatment, targeting a driver of cyst progression, shows promise in slowing or reversing the disease with minimal side effects.
Researchers found that immune cells in the gut follow an atypical pathway to produce antibodies providing long-term protection against viruses. The study could help guide the development of better vaccines for respiratory viruses like influenza and SARS-CoV-2.
Researchers have developed an innovative antibody-based enzyme switch called 'Switchbody', which is activated upon antigen binding. The switch's mechanism relies on a 'trap-and-release' process, offering new opportunities in diagnostics and therapeutics.
In response to rising RSV cases, ECDC advises policymakers and public health authorities on effective ways to mitigate the impact of RSV disease in infants. Immunisation interventions, including long-acting monoclonal antibodies and maternal vaccines, can prevent severe illness and hospitalization.
A 47-year-old man from New Jersey died after consuming beef due to a tick-borne meat allergy caused by the Lone Star tick's alpha-gal sugar. Researchers identified the allergy and its link to fatal anaphylaxis, urging physicians to investigate severe abdominal pain after eating red meat in areas with high Lone Star tick populations.
Researchers at the University of Pittsburgh have developed a skin patch test that can detect antibodies associated with COVID and flu infections. The test uses carbon nanotubes and is orders of magnitude more sensitive than existing tests.
Researchers developed a protein language model that can generate functional antibodies against specific viral antigens. This approach enables rapid generation of antibodies against emerging health threats without requiring blood samples or antigen proteins.
Researchers discover tiny antibody-like proteins from camels and llamas that can treat brain disorders like schizophrenia and Alzheimer’s disease with fewer side effects. The nanobodies are smaller than conventional antibodies, making them easier to produce and purify.
A randomized clinical trial has shown that rituximab is effective in preventing relapses and reducing the need for corticosteroids in adults with relapsing nephrotic syndrome. The study involved 66 adult patients treated with either rituximab or a placebo, with impressive results at the 49-week follow-up.